Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients
Open Access
- 23 July 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (7) , e0201113
Abstract
Therapeutic drug monitoring (TDM) of tacrolimus, based on blood concentrations, shows an imperfect correlation with the occurrence of rejection. Here, we tested whether measuring NFATc1 amplification, a member of the calcineurin pathway, is suitable for TDM of tacrolimus. NFATc1 amplification was monitored in T cells of kidney transplant recipients who received either tacrolimus- (n = 11) or belatacept-based (n = 10) therapy. Individual drug effects on NFATc1 amplification were studied in vitro, after spiking blood samples of healthy volunteers with either tacrolimus, belatacept or mycophenolate mofetil. At day 30 after transplantation, in tacrolimus-treated patients, NFATc1 amplification was inhibited in CD4+ T cells expressing the co-stimulation receptor CD28 (mean inhibition 37%; p = 0.01) and in CD8+CD28+ T cells (29% inhibition; p = 0.02), while this was not observed in CD8+CD28- T cells or belatacept-treated patients. Tacrolimus pre-dose concentrations of these patients correlated inversely with NFATc1 amplification in CD28+ T cells (rs = -0.46; p < 0.01). In vitro experiments revealed that 50 ng/ml tacrolimus affected NFATc1 amplification by 58% (mean; p = 0.02). In conclusion, measuring NFATc1 amplification is a direct tool for monitoring biological effects of tacrolimus on T cells in whole blood samples of kidney transplant recipients. This technique has potential that requires further development before it can be applied in daily practice.Keywords
This publication has 48 references indexed in Scilit:
- Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patientsExpert Opinion on Drug Metabolism & Toxicology, 2017
- High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive RegimeTransplantation, 2017
- Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-AnalysisPLOS ONE, 2015
- Intra-patient variability in tacrolimus exposure: Causes, consequences for clinical managementTransplantation Reviews, 2015
- OPTN/SRTR 2013 Annual Data Report: KidneyAmerican Journal of Transplantation, 2015
- Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized-Controlled Clinical TrialsAmerican Journal of Transplantation, 2013
- Therapeutic monitoring of Tacrolimus: Aberrant results by an immunoassay with automated pretreatmentClinica Chimica Acta, 2010
- Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus ConferenceTherapeutic Drug Monitoring, 2009
- Immunosuppression: Evolution in Practice and Trends, 1994–2004American Journal of Transplantation, 2006
- Therapeutic drug monitoring for immunosuppressantsClinica Chimica Acta, 2001